SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 5.02|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 15, 2022, the board of directors (the “Board”) of Alpine Immune Sciences, Inc. (the “Company”), based upon a recommendation from the Nominating and Corporate Governance Committee of the Board, voted to appoint Jörn Drappa as a director of the Company, effective July 18, 2022. Dr. Drappa was appointed as a Class II director with a term expiring at the Company’s 2023 annual meeting of stockholders.
Dr. Drappa will not be named to any committees of the Board in connection with his appointment.
There are no transactions and no proposed transactions between Dr. Drappa or any member of his immediate family and the Company or its subsidiaries, and there is no arrangement or understanding between Dr. Drappa and any other person or entity pursuant to which Dr. Drappa was appointed as a director of the Company.
Dr. Drappa will participate in the Company’s standard compensation plan for non-employee directors, including an initial stock option grant, which was granted to Dr. Drappa on July 18, 2022. The standard compensation plan for non-employee directors is described in the section titled “Board of Directors and Corporate Governance — Non-Employee Director Compensation — Director Compensation Policy” of the Company’s definitive proxy statement on Schedule 14A filed on April 29, 2022. In addition, the Company will enter into its standard form of indemnification agreement with Dr. Drappa.
In addition, on July 13, 2022, Dr. Jay Venkatesan submitted his resignation from the Board effective July 18, 2022. Dr. Venkatesan’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
A press release announcing Dr. Drappa’s appointment to the Board is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|Item 9.01|| |
Financial Statements and Exhibits.
|99.1||Press Release dated July 19, 2022.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: July 19, 2022||ALPINE IMMUNE SCIENCES, INC.|
|Title:||Senior Vice President and Chief Financial Officer|
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
- 20-year industry veteran with extensive global clinical development leadership experience in autoimmune and inflammatory diseases -
Seattle, WA July 19, 2022Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors.
We are very pleased to welcome Dr. Drappa to our Board of Directors. Jörn brings a tremendous depth of experience leading the successful development of immunology drugs across both small biotech and large pharmaceutical companies, and from early stage through commercialization, said Mitchell H. Gold, MD, Executive Chairman and Chief Executive Officer of Alpine. As a biotech executive with a proven track record and a board-certified internist and rheumatologist, Jörn will bring a unique perspective to our Board and provide valuable guidance as we continue to advance multiple clinical programs, including ALPN-303, a potentially best-in-class dual B-cell cytokine antagonist of BAFF and APRIL being developed for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
Dr. Drappa commented, Using their proprietary directed evolution platform, Alpine has rapidly developed multiple novel and differentiated multi-targeted immunotherapies with the potential to improve outcomes for patients suffering from serious diseases. Alpine is approaching several key catalysts and I am excited to join with the other Board members to help the team further advance their clinical pipeline across oncology and autoimmune and inflammatory indications.
Dr. Drappa most recently served as Chief Medical Officer of Ventyx Biosciences. Prior to Ventyx, Dr. Drappa co-founded Viela Bio, a biotechnology company focused on the discovery, development and commercialization of treatments for autoimmune and severe inflammatory diseases, and served as its Head of R&D and Chief Medical Officer through its acquisition by Horizon Therapeutics in March 2021 for $3.1 billion. At Viela Bio, Dr. Drappa led the development of UPLIZNA (inebilizumab-cdon) in multiple indications, culminating in its approval for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD). Prior to Viela Bio, he held various roles of increasing responsibility leading clinical development programs at MedImmune/AstraZeneca, Genentech/Roche, and Amgen. Dr. Drappa received his medical and Ph.D. degrees from the University of Cologne in Germany. He completed a residency in internal medicine at New York Presbyterian Hospital and a fellowship in rheumatology at the Hospital for Special Surgery, NY.
Concurrent with Dr. Drappa joining Alpines Board of Directors, Alpine also announced that Jay Venkatesan, MD has stepped down as a director of Alpine.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development. For more information, visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on Twitter and LinkedIn.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding Alpines platform technology and potential therapies; the potential efficacy, safety profile, future development plans, and regulatory success of Alpines product candidates; and Alpines ability to successfully develop and achieve milestones in Alpines development programs. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as may, will, should, would, expect, plan, intend, and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond Alpines control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of Alpines product candidates; Alpines discovery-stage and preclinical programs may not advance into the clinic or result in approved products; any of Alpines product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; adverse conditions in the general domestic and global economic markets; the impact of the COVID-19 pandemic on Alpines business, research and clinical development plans and timelines and results of operations may be more severe and prolonged than currently anticipated; as well as the other risks identified in Alpines filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Alpine undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Director, Investor Relations and Corporate Development
Alpine Immune Sciences, Inc
Source: Alpine Immune Sciences Inc.